News
Metagenomic Analyses Reveal Distinct Gut Microbiota Signature for Predicting the Neoadjuvant Chemotherapy Responsiveness in Breast Cancer Patients
Growing evidence supports the modulatory role of human gut microbiome on neoadjuvant chemotherapy (NAC) efficacy. However, the relationships among the gut microbiome, tumor-infiltrating lymphocytes (TILs), and NAC response for breast cancer (BC) patients remain unclear. We thus proposed this preliminary study to investigate the relationship between gut microbiome and BC patients’ responses to NAC treatment as well as underlying mechanisms.
Deciphering the Microbiome-Immunity-Cancer Axis
Trillions of microbes inhabit human body surfaces and cavities and interact with the host constantly. Recently, it came to light that the microbiota is a critical regulator of tumorigenesis and impacts outcomes of various cancer therapies.
Targeting the gut and tumor microbiota in cancer
Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as shaping cancer immunosurveillance and response to immunotherapy.
Press Releases
A trial of one of Igen Biolab Group’s products to investigate Age-Related Macular Degeneration (AMD) is approved
Javier Asarta, CEO of the Igen Biolab Group: “AMD affects some 700,000 people in Spain and currently has no treatment”.Dr Jordi Monés, study author: “As well as the medical benefits for patients, it reduces the socio-economic burden by preventing or improving the...
Biotech company Igen Biolab Group to raise up to EUR 15m for its clinical trials on lung cancer
Madrid, April 25, 2019.- Igen Biolab Group, a Spanish-based biotech company focused on the study of the microbiota impact on the prevention and treatment of cancer, and of neurodegenerative and metabolic diseases, has opened a financing round of up to 15 million euros...
New sponsorship for culture by IGEN Biotech
Among his Corporate Social Responsibility strategy, IGEN Biotech has expanded his programs of sponsorship on culture with a new agreement with the Culture Department of the regional Government of Catalonia (Spain), the Council of Barcelona, La Vanguardia,...
Events
International Conference on Microbiome Research
The International Research Conference will be held on march 11-12, 2022 in Miami, United States.
7th Annual Translational Microbiome Conference
Arrowhead Publishers is pleased to announce the return of the 7th Annual Translational Microbiome Conference – live and in-person, on April 13-14, 2022 in Washington DC.
10th Microbiome Interactions in Health and Disease meeting
The 10th Microbiome Interactions in Health and Disease meeting will once again bring together leading scientists and clinicians from the fields of microbiology, gastroenterology, neuroscience and public health to discuss the latest developments in this fast-moving area.
Publications
Metagenomic Analyses Reveal Distinct Gut Microbiota Signature for Predicting the Neoadjuvant Chemotherapy Responsiveness in Breast Cancer Patients
Growing evidence supports the modulatory role of human gut microbiome on neoadjuvant chemotherapy (NAC) efficacy. However, the relationships among the gut microbiome, tumor-infiltrating lymphocytes (TILs), and NAC response for breast cancer (BC) patients remain unclear. We thus proposed this preliminary study to investigate the relationship between gut microbiome and BC patients’ responses to NAC treatment as well as underlying mechanisms.
Deciphering the Microbiome-Immunity-Cancer Axis
Trillions of microbes inhabit human body surfaces and cavities and interact with the host constantly. Recently, it came to light that the microbiota is a critical regulator of tumorigenesis and impacts outcomes of various cancer therapies.
Targeting the gut and tumor microbiota in cancer
Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as shaping cancer immunosurveillance and response to immunotherapy.
